Sign In
Sign Up
Two Blokes
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
click to rate
Posted by
Two Blokes
Jul 16
- Filed in
Stock
- 2 views
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
